Showing 401-410 of 1775 results for "".
Adopting Epi-On CXL for KC
https://modernod.com/videos/eye-care-insiders/adopting-epi-on-cxl-for-kc/57127/In this episode, Joseph J. Allen, OD, FAAO, Dipl ABO, talks about optometry’s adoption of epithelial-on corneal crosslinking, FDA-approved in late 2025. As the procedure becomes more widely commercially available, Dr. Allen stresses the importance of understanding not only how it differs from epithe64. Get That Money Honey! Ft. Dr. Emilie Seitz
https://modernod.com/podcasts/four-eyes/64-get-that-money-honey-ft-dr-emilie-seitz/37014/Negotiating a contract as a new grad OD can be as terrifying as the first day of Optometry school. That’s why we’ve invited Dr. Emilie Seitz to the Four Eyes podcast to provide tips on negotiating contracts, identifying red flags, discussing money, and how to prioritize your needs. Dr. Seitz also sh[Genetics and Eyecare Today] How CXL and Genetic Testing Fit Into the Keratoconus Game Plan
https://modernod.com/podcasts/the-mod-pod/genetics-and-eyecare-today-how-cxl-and-genetic-testing-fit-into-the-keratoconus-game-plan/36816/The season finale of The MOD Pod’s mini series Genetics and Eyecare Today features Nicole Fram, MD, and Melissa Barnett, OD, FAAO, FSLS, FBCLA. Dr. Fram explains what corneal collagen crosslinking is and shares her protocol for administering the therapy. She also describes the typical situation in wA Decade of Developments in Glaucoma Management
https://modernod.com/videos/eye-care-insiders/a-decade-of-development-in-glaucoma-management/37354/Joseph J. Allen, OD, FAAO, Dipl ABO, highlights some of the biggest game-changers in glaucoma management from the past decade, from microinvasive glaucoma surgery to new therapeutics to the acceptance of selective laser trabeculoplasty as a primary therapeutic option for glaucoma.How to (Respectfully) Correct a Patient
https://modernod.com/videos/eye-care-insiders/eci-video-january-2025/37352/Joseph J. Allen, OD, FAAO, Dipl ABO, offers some best practices on an important aspect of patient education: addressing eye care misinformation. He shares several main points to keep in mind for (kindly and professionally) navigating these difficult conversations—especially when a patient insists thHighlights From MOD Live 2024 in Nashville
https://modernod.com/podcasts/the-mod-pod/highlights-from-mod-live-2024-in-nashville/36865/In this special episode of The MOD Pod, Cecelia Koetting, OD, FAAO, Dipl ABO, interviews a diverse group of attendees from MOD Live 2024. She speaks with program chairs, faculty, newcomers, and returning attendees, capturing a wide range of perspectives.Treatment Tactics for RCE
https://modernod.com/topics/corneaanterior-segment/eye-care-insiders-oct-video-2023/37331/Joseph J. Allen, OD, FAAO, Dipl ABO, reviews best practices for the treatment of recurrent corneal erosion (RCE). He discusses conditions that tend to co-occur with RCE, how to diagnose RCE, and strategies for management, along with insights on what treatments have worked well for his patients.Patients Do the Darndest Things …
https://modernod.com/videos/eye-care-insiders/patients-do-the-darndest-things/37340/Joseph J. Allen, OD, FAAO, Dipl ABO, shares a lighthearted top 10 list of things patients do that drive him crazy. Are you familiar with the chin tippers, dramatic photophobes, pull backers, and others that he mentions?Ryzumvi Rundown
https://modernod.com/videos/eye-care-insiders/eye-care-insiders-nov-2023-video/37334/Joseph J. Allen, OD, FAAO, Dipl ABO, spends this episode of Eye Care Insiders discussing phentolamine ophthalmic solution 0.75% (Ryzumvi, Ocuphire Pharma), explaining how it works, reviewing clinical trial findings, potential adverse events, how it could fit into your clinic, and more.The Future of Treating Diabetic Eye Disease?
https://modernod.com/topics/retina/eci-april-2023-video/37324/Joseph Allen, OD, FAAO, Dipl ABO, reviews everything you want to know about novel eye drop OTT166 (OcuTerra Therapeutics), which is in development for the treatment of diabetic retinopathy and diabetic macular edema, including its mechanism of action, pathway to the retina, and promising preliminary